Background: Platelet-derived growth factor (PDGF) is a potent activator of mesangial cell proliferation and migration. Although phosphoinositide 3-kinase (PI3K) enzymes are important downstream targets of the PDGF receptor, the contribution made by their 3-phosphoinositide products in the reorganization of actin cytoskeleton and focal adhesions has been questioned. Methods and Results: Pharmacological inhibition of the PI3K activity blocks PDGF-induced migration of human primary mesangial cells using an in vitro scrape wound healing assay. Acute (<10 min) inhibition of the PI3K activity did not alter the effect of PDGF on either stress fibre dissolution or reorganization of focal adhesions. However, at later times (>30 min), PDGF-stimulated responses were inhibited. In contrast, PDGF-stimulated membrane ruffling remained insensitive to PI3K inhibitors throughout. Inhibition of protein kinase C and Erk also attenuated PDGF-stimulated mesangial cell migration; however, neither signaling pathway was responsible for the initial effects on filamentous actin and focal adhesions. Conclusions: We propose that following PDGF stimulation of mesangial cells, reorganization of the actin cytoskeleton occurs in a biphasic manner. The mechanism responsible for mesangial cell migration that occurs immediately following PDGF stimulation may serve to ‘prime’ for the subsequent 3-phosphoinositide-, protein-kinase-C-, and Erk-dependent migration.

1.
Floege J: Glomerular remodelling: novel therapeutic approaches derived from the apparently chaotic growth factor network. Nephron 2002;91:582–587.
2.
Kagami S, Urushihara M, Kitamura A, Kondo S, Hisayama T, Kitamura M, Loster K, Reutter W, Kuroda Y: PDGF-BB enhances alpha1beta1 integrin-mediated activation of the ERK/AP-1 pathway involved in collagen matrix remodeling by rat mesangial cells. J Cell Physiol 2004;198:470–478.
3.
Floege J, Eitner F, van Roeyen C, Ostendorf T: PDGF-D and renal disease: yet another one of those growth factors? J Am Soc Nephrol 2003;14:2690–2691.
4.
Heldin CH, Ostman A, Rönnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79–F113.
5.
Hudkins KL, Gilbertson DG, Carling M, Taneda S, Hughes SD, Holdren MS, Palmer TE, Topouzis S, Haran AC, Feldhaus AL, Alpers CE: Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 2004;15:286–298.
6.
Eitner F, Ostendorf T, Kretzler M, Cohen CD, Eriksson U, Grone HJ, Floege J: PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol 2003;14:1145–1153.
7.
Kazlauskas A, Cooper JA: Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 1989;58:1121–1133.
8.
Shimamura H, Terada Y, Okado T, Tanaka H, Inoshita S, Sasaki S: The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad. J Am Soc Nephrol 2003;14:1427–1434.
9.
Iida H, Seifert R, Alpers CE, Gronwald RG, Phillips PE, Pritzl P, Gordon K, Gown AM, Ross R, Bowen-Pope DF, Johnson RJ: Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci USA 1991;88:6560–6564.
10.
Lindahl P, Hellström M, Kalen M, Karlsson L, Pekny M, Pekna M, Soriano P, Betsholtz C: Paracrine PDGF-B/PDGF-Rbeta signaling controls mesangial cell development in kidney glomeruli. Development 1998;125:3313–3322.
11.
Sano H, Ueda Y, Takakura N, Takemura G, Doi T, Kataoka H, Murayama T, Xu Y, Sudo T, Nishikawa S, Nishikawa S, Fujiwara H, Kita T, Yokode M: Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am J Pathol 2002;161:135–143.
12.
Bjarnegard M, Enge M, Norlin J, Gustafsdottir S, Fredriksson S, Abramsson A, Takemoto M, Gustafsson E, Fassler R, Betsholtz C: Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 2004;131:1847–1857.
13.
Suzuki A, Iwatani H, Ito T, Imai E, Okabe M, Nakamura H, Isaka Y, Yamato M, Hori M: Platelet-derived growth factor plays a critical role to convert bone marrow cells into glomerular mesangial-like cells. Kidney Int 2004;65:15–24.
14.
Ostendorf T, Kunter U, van Roeyen C, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J: The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 2002;13:658–667.
15.
Rönnstrand L, Heldin CH: Mechanisms of platelet-derived growth factor-induced chemotaxis. Int J Cancer 2001;91:757–762.
16.
Jaffe AB, Hall A: Cell biology. Smurfing at the leading edge. Science 2003;302:1690–1691.
17.
Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR: Cell migration: integrating signals from front to back. Science 2003;302:1704–1709.
18.
Choudhury GG, Grandaliano G, Jin DC, Katz MS, Abboud HE: Activation of PLC and PI 3 kinase by PDGF receptor alpha is not sufficient for mitogenesis and migration in mesangial cells. Kidney Int 2000;57:908–917.
19.
Crean JK, Finlay D, Murphy M, Moss C, Godson C, Martin F, Brady HR: The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem 2002;277:44187–44194.
20.
Nelson PJ, Moissoglu K, Vargas J Jr, Klotman PE, Gelman IH: Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. J Cell Sci 1999;112(Pt 3):361–370.
21.
Gruden G, Thomas S, Burt D, Lane S, Chusney G, Sacks S, Viberti G: Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci USA 1997;94:12112–12116.
22.
Blom IE, van Dijk AJ, Wieten L, Duran K, Ito Y, Kleij L, deNichilo M, Rabelink TJ, Weening JJ, Aten J, Goldschmeding R: In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 2001;16:1139–1148.
23.
Domin J, Harper L, Aubyn D, Wheeler M, Florey O, Haskard D, Yuan M, Zicha D: The class II phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P dependent mechanism. J Cell Physiol 2005;205:452–462.
24.
Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, De Laurentiis A, Downward J, Scita G, Ridley AJ, Waterfield MD, Arcaro A: Phosphoinositide 3-kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 2006;17:3729–3744.
25.
Prigozhina NL, Waterman-Storer CM: Decreased polarity and increased random motility in PtK1 epithelial cells correlate with inhibition of endosomal recycling. J Cell Sci 2006;119:3571–3582.
26.
Barnes JL, Hevey KA: Glomerular mesangial cell migration. Response to platelet secretory products. Am J Pathol 1991;138:859–866.
27.
Merlot S, Firtel RA: Leading the way: directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. J Cell Sci 2003;116:3471–3478.
28.
Welch HC, Coadwell WJ, Stephens LR, Hawkins PT: Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett 2003;546:93–97.
29.
Cote JF, Motoyama AB, Bush JA, Vuori K: A novel and evolutionarily conserved PtdIns(3,4,5)P3-binding domain is necessary for DOCK180 signalling. Nat Cell Biol 2005;7:797–807.
30.
Tolias KF, Cantley LC, Carpenter CL: Rho family GTPases bind to phosphoinositide kinases. J Biol Chem 1995;270:17656–17659.
31.
Weiner OD, Neilsen PO, Prestwich GD, Kirschner MW, Cantley LC, Bourne HR: A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol 2002;4:509–513.
32.
Funamoto S, Meili R, Lee S, Parry L, Firtel RA: Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell 2002;109:611–623.
33.
Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 2004;303:1179–1181.
34.
Greenwood JA, Theibert AB, Prestwich GD, Murphy-Ullrich JE: Restructuring of focal adhesion plaques by PI 3-kinase. Regulation by PtdIns(3,4,5)-p(3) binding to alpha-actinin. J Cell Biol 2000;150:627–642.
35.
Kruger JS, Reddy KB: Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 2003;1:801–809.
36.
Willis AI, Fuse S, Wang XJ, Chen E, Tuszynski GP, Sumpio BE, Gahtan V: Inhibition of phosphatidylinositol 3-kinase and protein kinase C attenuates extracellular matrix protein-induced vascular smooth muscle cell chemotaxis. J Vasc Surg 2000;31:1160–1167.
37.
Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE: Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997;29:334–339.
38.
Knall C, Worthen GS, Johnson GL: Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc Natl Acad Sci USA 1997;94:3052–3057.
39.
Choudhury GG, Biswas P, Grandaliano G, Fouqueray B, Harvey SA, Abboud HE: PDGF-mediated activation of phosphatidylinositol 3 kinase in human mesangial cells. Kidney Int 1994;46:37–47.
40.
Campbell M, Trimble ER: Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII. Circ Res 2005;96:197–206.
41.
Raftopoulou M, Hall A: Cell migration: Rho GTPases lead the way. Dev Biol 2004;265:23–32.
42.
Buday L, Wunderlich L, Tamas P: The Nck family of adapter proteins: regulators of actin cytoskeleton. Cell Signal 2002;14:723–731.
43.
Grimsley CM, Kinchen JM, Tosello-Trampont AC, Brugnera E, Haney LB, Lu M, Chen Q, Klingele D, Hengartner MO, Ravichandran KS: Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration. J Biol Chem 2004;279:6087–6097.
44.
Plevin R, Cook SJ, Palmer S, Wakelam MJ: Multiple sources of sn-1,2-diacylglycerol in platelet-derived-growth-factor-stimulated Swiss 3T3 fibroblasts. Evidence for activation of phosphoinositidase C and phosphatidylcholine-specific phospholipase D. Biochem J 1991;279(Pt 2):559–565.
45.
Domin J, Rozengurt E: Platelet-derived growth factor stimulates a biphasic mobilization of arachidonic acid in Swiss 3T3 cells. The role of phospholipase A2. J Biol Chem 1993;268:8927–8934.
46.
Susa M, Thomas G: Identical Mr 70,000 S6 kinase is activated biphasically by epidermal growth factor: a phosphopeptide that characterizes the late phase. Proc Natl Acad Sci USA 1990;87:7040–7044.
47.
Wilkes MC, Murphy SJ, Garamszegi N, Leof EB: Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol 2003;23:8878–8889.
48.
Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3:807–821.
49.
Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J, Abboud HE: PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. Am J Physiol 1997;273(6 Pt 2):F931–F938.
50.
Cross MJ, Stewart A, Hodgkin MN, Kerr DJ, Wakelam MJ: Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 1995;270:25352–25355.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.